nVector

Executive Summary

nVector is a San Diego-based biotechnology company pioneering a proprietary adeno-associated virus (AAV) platform for central nervous system (CNS) gene therapy. Its core GreenGlia™ technology enables precise targeting of glial and neuronal cell types, addressing key delivery barriers that have historically limited CNS gene therapies. The platform holds potential for treating devastating neurodegenerative diseases such as ALS, Parkinson's, and Huntington's, which currently lack effective disease-modifying treatments. nVector also offers biomarker testing services to support CNS drug development. Founded in 2016, the company operates in the drug delivery and viral technology sectors, positioning itself as an enabler of next-generation gene therapies for challenging CNS targets. The company's approach is particularly compelling given the growing interest in gene therapy for neurological disorders and the limitations of existing AAV vectors. By achieving cell-type specificity, nVector aims to improve efficacy and safety profiles, potentially unlocking new therapeutic opportunities. While still in early stages (no disclosed stage or funding details), its technology has the potential to attract partnerships with larger pharmaceutical companies seeking CNS gene therapy solutions. Key upcoming milestones include preclinical validation data, strategic collaborations, and potential IND-enabling studies. The success of nVector hinges on demonstrating in vivo targeting selectivity and translating its platform into meaningful clinical candidates.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a strategic partnership with a major pharmaceutical company for CNS gene therapy development45% success
• Q3 2026Release of preclinical proof-of-concept data in a neurodegenerative disease model (e.g., ALS or Huntington's)60% success
• Q2 2027Completion of Series A financing or grant award to advance GreenGlia™ platform50% success